Connect with us

Company News

Butterfly Network reports Q4 2023 financial results

Butterfly Network, Inc. announced financial results for the quarter and year ended December 31, 2023, and provided a business update.

Joseph DeVivo, Butterfly’s Chairman and CEO said, “2023 was a transition year for Butterfly as we delivered on our initiatives and focused on rightsizing our business by resizing our cost base, refocusing our product and growth strategy, and investing in our go-to-market channels. The team’s hard work in executing our plan has laid a solid foundation for Butterfly to grow on in 2024 and onwards.”

DeVivo continued, “Throughout 2023, and more recently, we invested in and launched the products and applications that will propel our growth initiatives. Ahead of schedule in early 2024, we received Food and Drug Administration clearance on, and subsequently launched, our third-generation point-of-care ultrasound system, Butterfly iQ3™. Powered by our most advanced semiconductor chip, the iQ3 has an unparalleled image quality and advanced 3D capabilities that now rival competitors’ offerings – all in a more easily accessible format and significantly lower price point.”

“Advances in our technology continue to attract exciting partnerships that further expands our Butterfly Garden and Powered by Butterfly ecosystems. This growing network, coupled with our own advances in ultrasound AI, and our recent launch of a new educational app ScanLab™, will help drive adoption, to fuel near-term growth. On the international front, we look forward to strengthening our offerings in Europe, while we enter the Asian market with iQ+™.”

“We are excited about what 2024 has in store for Butterfly and are confident in our growth prospects. I look forward to sharing more about our growth initiatives, include home and wearables, at our upcoming Investor Day at the New York Stock Exchange.”

Three months ended December 31, 2023 financial results
Revenue: Total revenue was $16.5 million, down from $19.0 million in the fourth quarter of 2022. U.S. revenue was $10.9 million, down 3% from prior year, driven by lower probe sales but partially offset by higher subscription revenue and higher average selling prices. International sales declined 24% year-over-year to $4.6 million due to several large orders from distributors that occurred in 2022 and did not repeat in 2023.

  • Product revenue was $10.2 million, a decrease of 20% versus the prior year period, driven by the distributor orders in 2022 and lower ecommerce volume.
  • Software and other services revenue was flat year-over-year at $6.4 million. Enterprise software grew by 35% versus the prior year while individual licenses and service revenue were down. Software and services mix was 39% of revenue and increased by 5% versus prior year due to a higher installed base of product with the accompanying subscription software, renewals on the existing base of software users, and software implementations completed during the quarter.

Gross profit: Gross loss was $12.5 million versus gross profit of $9.6 million in the prior year period, and adjusted gross profit was $9.4 million versus $10.3 million in the prior year period. Total gross margin decreased to negative 75.9% from 50.3% in the prior year period, and adjusted gross margin increased to 56.6% from 54.5% in the prior year period. The decrease in total gross margin is primarily due to a $21.9 million write-down of excess and obsolete inventory that was recognized during the quarter, which is excluded from adjusted gross profit and adjusted gross margin. The increase in adjusted gross margin was primarily due to a higher average selling price, in addition to product mix, reflecting a higher proportion of subscription revenues. Also contributing to the increased margin was higher manufacturing productivity and other efficiencies. Offsetting these benefits was higher amortization which reduced margin by approximately 240 basis points.

Operating expenses: Operating expenses were $34.2 million, down 42% from $58.6 million in the prior year period, due to previously announced reductions in force, as well as non-payroll spend rationalization across all areas.

Total operating expenses excluding stock-based compensation and Other expense were $27.3 million, compared to $39.9 million in the fourth quarter of 2022, representing a decrease of 32%.

Net loss: Net loss was $44.1 million, compared to $33.7 million in the prior year period.

Adjusted EBITDA: Adjusted EBITDA loss was $15.7 million, compared to $27.7 million in the prior year period.

Cash, cash equivalents, and restricted cash: Cash, cash equivalents, and restricted cash were $138.7 million as of December 31, 2023.

Guidance
For the fiscal year 2024:

  • Low double digit Revenue growth
  • Adjusted EBITDA loss of $60 million – $50 million

A reconciliation of net loss to adjusted EBITDA and Gross Margin to Adjusted Gross Margin for the three months and years ended December 31, 2023, and 2022 is provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!